Publication | Closed Access

Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3weeks in solid tumours: An ECSG/EORTC study

OncologyEcsg/eortc StudyPharmacologySolid TumoursSingle DoseRadiopharmaceutical TherapyPharmacotherapyAnti-cancer AgentMedicineRadiation OncologyPharmacokineticsCancer Research